R&D
Breakdown
Segments
ARIKAYCE external R&D expensesView metric
Brensocatib external R&D expensesView metric
TPIP external R&D expensesView metric
Other external R&D expensesView metric
INS1148View metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| TPIP external R&D expenses | $14.77M | $16.64M | $20.75M | $9.15M | $20.65M | $28.75M | $35.65M | $37.34M |
| Other external R&D expenses | $14.92M | $26.92M | $35.49M | $28.08M | $28.45M | $36.58M | $36.76M | $32.68M |
| Brensocatib external R&D expenses | $37.81M | $17.29M | $23.96M | $20.66M | $33.56M | $19.36M | $22.94M | $18.48M |
| ARIKAYCE external R&D expenses | $14.90M | $16.37M | $15.08M | $12.12M | $11.00M | $9.21M | $9.10M | $8.62M |
| Total | $146.75M | $150.81M | $179.73M | $152.58M | $177.19M | $186.42M | $254.91M | $209.49M |
INS1148 is derived from annual filings.